Alenazy Rawaf
Department of Medical Laboratory, College of Applied Medical Sciences-Shaqra, Shaqra University, Shaqra 11961, Saudi Arabia.
Biology (Basel). 2022 Sep 8;11(9):1328. doi: 10.3390/biology11091328.
Infections caused by multidrug resistance (MDR) of Gram-negative bacteria have become one of the most severe public health problems worldwide. The main mechanism that confers MDR to bacteria is drug efflux pumps, as they expel a wide range of compounds, especially antibiotics. Among the different types of drug efflux pumps, the resistance nodulation division (RND) superfamily confers MDR to various Gram-negative bacteria species. The AcrAB-TolC multidrug efflux pump, from , a member of RND, is the best-characterized example and an excellent model for understanding MDR because of an abundance of functional and structural data. Small molecule inhibitors that target the AcrAB-TolC drug efflux pump represent a new solution to reversing MDR in Gram-negative bacteria and restoring the efficacy of various used drugs that are clinically relevant to these pathogens, especially in the high shortage of drugs for multidrug-resistant Gram-negative bacteria. This review will investigate solutions of MDR in Gram-negative bacteria by studying the inhibition of the AcrAB-TolC multidrug efflux pump.
革兰氏阴性菌的多重耐药性（MDR）引起的感染已成为全球最严重的公共卫生问题之一。赋予细菌多重耐药性的主要机制是药物外排泵，因为它们能排出多种化合物，尤其是抗生素。在不同类型的药物外排泵中，耐药结瘤分裂（RND）超家族赋予多种革兰氏阴性菌多重耐药性。来自RND成员的AcrAB-TolC多药外排泵是特征最明确的例子，也是理解多重耐药性的优秀模型，因为有大量的功能和结构数据。靶向AcrAB-TolC药物外排泵的小分子抑制剂是逆转革兰氏阴性菌多重耐药性并恢复与这些病原体临床相关的各种常用药物疗效的新解决方案，特别是在多重耐药革兰氏阴性菌药物严重短缺的情况下。本综述将通过研究对AcrAB-TolC多药外排泵的抑制作用来探讨革兰氏阴性菌多重耐药性的解决方案。
